<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03299036</url>
  </required_header>
  <id_info>
    <org_study_id>B-BR-105-054</org_study_id>
    <nct_id>NCT03299036</nct_id>
  </id_info>
  <brief_title>Drug-loadable（T-ACE Beads）for Hepatoma Embolization Therapy</brief_title>
  <official_title>Hydrophilic Radiopaque Microsphere With Doxorubicin for Hepatoma Embolization Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cheng-Kung University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Industrial Technology Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cheng Kung University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cheng-Kung University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of Radiopaque Microsphere&#xD;
      (T-ACE Beads with doxorubicin) interventional therapy for patients with liver cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will evaluate the safety and tolerability of Taiwan ACE Beads with doxorubicin used&#xD;
      for chemoembolization for the treatment of unresectable hepatocellular carcinoma.&#xD;
&#xD;
      The investigators will study the overall response rates of lesions with Taiwan ACE Beads.&#xD;
&#xD;
      The procedure is similar with the other commercializing drug-eluting beads. At the target&#xD;
      vessels, radiologists will inject doxorubicin with Taiwan ACE Beads instead of Gelfoam or PVA&#xD;
      (polyvinyl alcohol). The end point of injection is also similar with conventional TACE.&#xD;
&#xD;
      Determine the complication rates, progression free survival (PFS) and overall survival (OS)&#xD;
      following Taiwan ACE Beads embolization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Actual">October 16, 2018</completion_date>
  <primary_completion_date type="Actual">October 16, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patients Survival (Safety)</measure>
    <time_frame>An average of 12 weeks.</time_frame>
    <description>Survival rate will be evaluated since treatment day until the date of death or final observation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor response in patients with hepatoma who received Taiwan ACE beads (TACE) microspheres embolization evaluated with mRECIST criteria</measure>
    <time_frame>Three months</time_frame>
    <description>mRECIST criteria will be used to evaluate tumor response in patients with hepatoma who received Taiwan ACE beads (TACE) microspheres embolization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Level of AFP</measure>
    <time_frame>An average of 12 weeks</time_frame>
    <description>Collect Doxorubicin's blood concentration, 5 mL each time</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Cancer of Liver</condition>
  <arm_group>
    <arm_group_label>Taiwan ACE Beads with doxorubicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The use of Taiwan ACE Beads (T-ACE) microspheres embolization with doxorubicin as a treatment for patients with hepatoma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Taiwan ACE Beads with doxorubicin</intervention_name>
    <description>Similar with commercializing drug-eluting beads, radiologist inject Taiwan ACE Beads with doxorubicin instead of Gelfoam or polyvinyl alcohol.</description>
    <arm_group_label>Taiwan ACE Beads with doxorubicin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients must meet all of the following inclusion criteria in order to be entered into the&#xD;
        study:&#xD;
&#xD;
        A. Both genders of patients age 20 or older.&#xD;
&#xD;
        B. Patients diagnosed of liver cancer (MUST meet at least ONE of the following criteria:)&#xD;
&#xD;
          1. Diagnosed via tumor biopsy by Pathologists, and confirmed by on-service physician.&#xD;
&#xD;
          2. High risk patients (Viral hepatitis B or C or cirrhotics) with typical liver cancer&#xD;
             image appeared on more than two radiographic examinations (Ultrasound, MRI, CT scan or&#xD;
             Angiography).&#xD;
&#xD;
          3. High risk patients (Viral hepatitis B or C cirrhotics) with evidence of enlarging&#xD;
             image of liver cancer via more than two follow-up records.&#xD;
&#xD;
        C. In intermediate stage by BCLC staging, tumor size under 8 centimeters, with liver&#xD;
        function at Child-Pugh class ≤ 8, and is either difficult to accept an operation or&#xD;
        reluctant to accept any operation.&#xD;
&#xD;
        D. Disease can be treated by transarterial chemoembolization, and can be evaluated by&#xD;
        Ultrasound, Magnetic resonance imaging (MRI), or computed tomography (CT).&#xD;
&#xD;
        E. Performance status ECOG 2 or less. Patient has a life expectancy of at least 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        If patients meet any of the following criteria they may not be entered into the study:&#xD;
&#xD;
        A. major branch of portal vein has been invaded already; extrahepatic metastasis or the the&#xD;
        other malignant tumors.&#xD;
&#xD;
        B. Evidences of decompensation: Total Bilirubin&gt;2, PT prolong&gt;3 seconds, Child-Pugh&#xD;
        class&gt;8, refractory ascites, active bleeding, hepatic encephalopathy, and severe infection.&#xD;
&#xD;
        C. Tumor size (diameter) larger than 8 centimeters.&#xD;
&#xD;
        D. Not on dialysis with Creatinine &gt;2.0 mg/dL.&#xD;
&#xD;
        E. Allergic to iodine or other injections.&#xD;
&#xD;
        F. Other main organ failure (Heart, Lung, or Kidney).&#xD;
&#xD;
        G. WBC&lt;3000, or Platelet Count &lt;50,000 mg/dL.&#xD;
&#xD;
        H. Performance status ECOG of 3 or more.&#xD;
&#xD;
        I. Pregnant women and breath feeding women.&#xD;
&#xD;
        J. Patients whose blood vessel are too difficult to do Taiwan ACE Beads procedure.&#xD;
&#xD;
        K. Prominent AV shunt.&#xD;
&#xD;
        L. Severe atherosclerosis.&#xD;
&#xD;
        M. Vasospasm or possible major vascular injury.&#xD;
&#xD;
        N. Arteriovenous shunt patients, diameter larger than the size of microsphere available.&#xD;
&#xD;
        O. Collateral vascular exists and may endanger non-targeted area during arterial&#xD;
        chemoembolization.&#xD;
&#xD;
        P. Contraindications for doxorubicin.&#xD;
&#xD;
        Q. Numerous of tumors locate at different lobes, high risk of Hepatic insufficiency.&#xD;
&#xD;
        R. Unwilling to sign a written informed consent form.&#xD;
&#xD;
        S. Allergic to pharmaceutical excipients related to Microspheres.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xi-Zhang Lin</last_name>
    <role>Study Director</role>
    <affiliation>Department of Internal Medicine, National Cheng Kung University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Liu YS, Lin XZ, Tsai HM, Tsai HW, Chen GC, Chen SF, Kang JW, Chou CM, Chen CY. Development of biodegradable radiopaque microsphere for arterial embolization-a pig study. World J Radiol. 2015 Aug 28;7(8):212-9. doi: 10.4329/wjr.v7.i8.212.</citation>
    <PMID>26339465</PMID>
  </reference>
  <reference>
    <citation>Liu YS, Ou MC, Tsai YS, Lin XZ, Wang CK, Tsai HM, Chuang MT. Transarterial chemoembolization using gelatin sponges or microspheres plus lipiodol-doxorubicin versus doxorubicin-loaded beads for the treatment of hepatocellular carcinoma. Korean J Radiol. 2015 Jan-Feb;16(1):125-32. doi: 10.3348/kjr.2015.16.1.125. Epub 2015 Jan 9.</citation>
    <PMID>25598680</PMID>
  </reference>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>September 20, 2017</study_first_submitted>
  <study_first_submitted_qc>September 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2017</study_first_posted>
  <last_update_submitted>October 18, 2018</last_update_submitted>
  <last_update_submitted_qc>October 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatoma</keyword>
  <keyword>Transcatheter Arterial chemo-embolization</keyword>
  <keyword>Microsphere</keyword>
  <keyword>Doxorubicin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

